Déjà Vu, With a Twist: The Vaping Industry’s Approach to Youth-Oriented Advertising Via Social Media
Posted: February 12, 2020 Dr. Lisa Fucito As of early December 2019, the Centers for Disease Control and Prevention (CDC) have received reports from all 50 states, Puerto Rico, the […] Read more
Tumor Mutation Burden: Evolution of a Controversial Biomarker From the Pathologist’s Perspective
By Lynette M. Sholl, MD, and John W. Longshore, PhD, FACMG Posted: February 12, 2020 Dr. Lynette M. Sholl Dr. John W. Longshore The profound impact of immunotherapy in patients […] Read more
Increasing the Role of Local Consolidation in Oncogenic-Driven Advanced NSCLC
By Youquan Li, MD, FRCR, and Andrea Bezjak, MDCM, MSc, FRCPC Posted: February 12, 2020 Targeted agents including TKIs of EGFR, ALK, and ROS1 have significantly improved the outcomes of […] Read more
Treating Patients with MET Alterations: A Q&A with Dr. Ravi Salgia
Posted: February 12, 2020 Ravi Salgia, MD, PhD, is the Arthur & Rosalie Kaplan Endowed Chair in Medical Oncology and the associate director for clinical sciences at City of Hope’s […] Read more
By Alexander Drilon, MD Posted: February 12, 2020 The receptor tyrosine kinases TRKA/B/C are encoded by the genes NTRK1/2/3. TRK fusions are oncogenic drivers of various adult and pediatric cancers. […] Read more
Lung Cancer Surveillance After Definitive Curative-Intent Therapy: A Q&A With Dr. Edgardo S. Santos Castillero
Posted: February 12, 2020 Edgardo S. Santos Castillero, MD, FACP, is an IASLC Lung Cancer News Editorial Group Member and served as a co-chair on the expert panel that developed […] Read more
Doctor of Nursing Practice Project Aims to Educate Non-Oncology Providers About the Management of Immunotherapy AEs
By Enza Esposito Nguyen, DNP, RN, ANP-BC Posted: February 12, 2020 Dr. Enza Esposito Nguyen Although we continue to see many immunotherapy clinical trials mature and deliver marvelous improvements […] Read more
CheckMate 568: Efficacy and Biomarker Analysis for Nivolumab and Ipilimumab in NSCLC
By Neal Ready, MD, PhD Posted: February 12, 2020 Dr. Neal Ready Programmed death receptor (PD-1) checkpoint monoclonal antibody therapy has proven a major advancement in the management of advanced […] Read more
Posted: February 12, 2020 November 1, 2019—After years of political volleying and public outcry, Austria implemented a full indoor smoking ban in bars, cafes, and restaurants. With its capitol, Vienna, […] Read more
This article is the second in a two-part series on ongoing challenges using immunotherapy in special populations. The first part of this series focused on patients with poor performance status. […] Read more